RVMD241220C47000
- 0.60
- -0.80-57.14%
Revolution Medicines Newsroom
One Revolution Medicines Insider Raised Their Stake In The Previous Year
S&P 500 Futures Up In Premarket Trading; Oracle, Ferguson Enterprises Lag
Revolution Medicines Director Schroeder Acquires $59.9m in Stock
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $62
Wedbush Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $67
Express News | Revolution Medicines Inc : Needham Cuts Target Price to $62 From $68
Promising Outlook for Revolution Medicines: Strong Efficacy and Safety Data Boost Confidence in RMC-6236 and RMC-6291
Express News | Revolution Medicines Inc : Wedbush Cuts Target Price to $67 From $70
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $72
Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.
Revolution Medicines Price Target Raised to $72.00/Share From $64.00 by HC Wainwright & Co.
Top 3 Health Care Stocks That Could Blast Off In December
Revolution Medicines Prices Upsized $750M Offering of Common Stock, Pre-Funded Warrants >RVMD
Revolution Medicines Offering Is Expected to Close Dec. 5 >RVMD
Express News | Revolution Medicines Inc - Prices 14,130,436 Shares at $46.00 per Share
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $80
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $68 to $80
Express News | Revolution Medicines Inc : Guggenheim Raises Target Price to $87 From $82
Revolution Medicines' Promising RAS(ON) Portfolio and Strategic Growth Opportunities Justify Buy Rating